齐鲁晚报·齐鲁壹点记者 黄寿赓 市场经历"健康牛"，8月22日，A股三大股指再度大幅上涨，沪指站上3800点，自4月8日以来，累计涨幅达23.55%。持续上涨背后，上市公司中期分红密集 披露，Wind数据显示，目前已有超210家公司公布相关预案，分红总额达1354亿元（含税，下同）。近年来，在监管层倡导下，上市公司一年多次分红成新 风向，并为股指上涨提供支撑。 具体来看，中国移动"领衔"分红总额。中国移动披露，公司决定2025年中期派息每股2.75港元；总额折合约合人民币540.83亿元。上半年，中国移动实现收 入5437.69亿元，同比下降0.5%；实现归属于母公司股东的净利润842.35亿元，同比增长5%。 中国电信以165.81亿元居于次席。中国电信披露，公司拟向全体股东每股派发现金红利0.1812元。截至2025年6月30日，公司总股本915.07亿股，以此计算合 计拟派发现金红利165.81亿元，占报告期归属于公司股东的净利润人民币230.17亿元的72%。上半年，中国电信实现营业收入2694.22亿元，同比增长1.3%； 归属于上市公司股东的净利润为230.17亿元，同比增长5.5%。 中国联通的 ...

Core Viewpoint - Hansoh Pharmaceutical plans to raise HKD 3.9 billion through a rights issue, marking its third refinancing since its listing, with its stock price currently at approximately 80% of its historical high [1] Group 1: Financing Activities - Over 20 Hong Kong-listed innovative pharmaceutical companies have engaged in refinancing since the beginning of 2025, with total refinancing exceeding HKD 34 billion, significantly higher than the same period last year [1][3] - WuXi AppTec raised nearly HKD 7.7 billion through a share placement, making it the highest fundraising company in this round of refinancing [4] - Innovent Biologics raised approximately HKD 4.3 billion through the placement of 55 million new shares, with 90% of the funds allocated for global R&D and facility layout [4] Group 2: Stock Performance and Market Trends - The stock prices of many innovative pharmaceutical companies have doubled since the beginning of the year, indicating a market recovery [1] - Innovent Biologics' stock price has increased over 2.5 times this year, reflecting strong market performance [8] - The stock price of Hansoh Pharmaceutical is currently around HKD 36.6, close to its historical high of HKD 45 [5] Group 3: Shareholder Actions - Some founders and major shareholders are taking the opportunity to reduce their holdings and cash out, despite the positive market sentiment [4][7] - Notable reductions include a significant shareholder of BeiGene, who cashed out over USD 70 million in the U.S. market [7] - Major shareholders of Innovent Biologics, including Temasek and Eli Lilly Asia Fund, have also reduced their stakes, cashing out over HKD 2.4 billion each [8]

Group 1 - The report tracks stocks, industries, and sectors that are reaching new highs, serving as market indicators and highlighting the effectiveness of momentum and trend-following strategies [1][4][24] - As of August 22, 2025, the Shanghai Composite Index, Shenzhen Component Index, CSI 300, CSI 500, CSI 1000, CSI 2000, ChiNext Index, and Sci-Tech 50 Index all have a distance to their 250-day highs of 0.00%, indicating they are at their recent peaks [5][24] - Among the CITIC first-level industry indices, home appliances, defense and military, comprehensive, media, and computer industries are closest to their 250-day highs, while food and beverage, coal, real estate, banking, and consumer services are further away [8][24] Group 2 - A total of 1,606 stocks reached 250-day highs in the past 20 trading days, with the most significant numbers in the machinery, pharmaceuticals, and electronics sectors [2][13][24] - The highest proportion of new high stocks is found in the defense and military, non-ferrous metals, and pharmaceuticals industries, with respective proportions of 52.94%, 51.61%, and 44.88% [13][16] - The manufacturing and technology sectors have the most stocks reaching new highs this week, with respective counts of 512 and 403 [16][24] Group 3 - The report identifies 48 stocks that have shown stable new highs, with the technology and manufacturing sectors contributing the most, having 22 and 12 stocks respectively [3][21][25] - Within the technology sector, the electronics industry has the highest number of new high stocks, while the automotive industry leads in the manufacturing sector [21][25]

Core Viewpoint - The Hong Kong innovative pharmaceutical sector has seen a significant increase in refinancing activities in 2025, with over 20 companies participating, raising more than 34 billion HKD, which is substantially higher than the same period last year [1][2]. Group 1: Financing Activities - As of August 20, 2025, Hansoh Pharmaceutical announced a plan to raise 3.9 billion HKD through a rights issue, marking its third refinancing since listing [2]. - The total refinancing amount for Hong Kong innovative pharmaceutical companies has exceeded 34 billion HKD, with some companies conducting multiple rounds of refinancing [2][5]. - WuXi AppTec has raised the highest amount in this refinancing wave, securing nearly 7.7 billion HKD through a placement of new shares [7]. Group 2: Comparison with A-Shares - In contrast, only two A-share innovative pharmaceutical companies have been approved for refinancing this year: Dizal Pharmaceutical raised approximately 1.8 billion HKD in April, and Baillie Tianheng's 3.9 billion HKD plan was approved in early August [5]. Group 3: Shareholder Actions - Some founders and major shareholders of innovative pharmaceutical companies are taking the opportunity to reduce their holdings and cash out [6][13]. - Notable reductions include the founders of BeiGene, who have sold shares worth over 70 million USD in the U.S. market since the beginning of the year [13]. - Temasek, the largest shareholder of Innovent Biologics, has reduced its stake three times, cashing out over 2.4 billion HKD [14]. Group 4: Innovative Financing Methods - Several companies are utilizing "old-for-new" financing methods, where founders sell their old shares to new investors and use the cash to subscribe to newly issued shares, making it more attractive for investors [9][10]. - For instance, Ascentage Pharma raised 1.5 billion HKD through this method, coinciding with the approval of its second drug [10]. Group 5: Market Trends - The innovative pharmaceutical sector has experienced a surge in stock prices, with many companies actively seeking financing to support future growth [13]. - Innovent Biologics has seen its stock price increase by over 2.5 times since the beginning of the year, while WuXi AppTec's stock price is close to its historical high [14].

Group 1 - Jiangsu Securities Regulatory Bureau has enhanced its regular visiting mechanism for listed companies, achieving a coverage rate of 64.78% by visiting 458 companies as of July 31, 2023, and resolving 446 issues to promote better development [1] - The bureau focuses on key industries, such as automotive and home appliances, to help companies leverage national policies for quality improvement and efficiency, with nearly 90% of related companies achieving profitability [2] - In the pharmaceutical sector, the bureau has guided innovative drug companies to utilize capital markets for upgrades, with one company successfully obtaining FDA approval for a new drug [2] Group 2 - The bureau supports listed companies in financing and mergers, with equity financing reaching 51.233 billion yuan from January to July 2023, and 209 new merger and acquisition disclosures, totaling over 65.084 billion yuan [3] - A total of 83 listed companies in Jiangsu have announced buyback or increase plans, amounting to 15.924 billion yuan, while 160 companies plan to conduct mid-term dividends, a 11.72% increase year-on-year [4] - The bureau has established strategic cooperation agreements with 13 cities to enhance communication and support for listed companies, leading to the stable delisting of 6 ST companies this year [5]

FF305 呈交日期： 2025年8月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月 ...

该信息由智通财经网提供 智通财经APP讯，药明康德(02359)发布公告，于2025年8月22日斥资2999.46万元回购A股股份32.35万 股，每股回购价格为91.35-93.92元。 ...

药明康德（603259）(02359)发布公告，于2025年8月22日斥资2999.46万元回购A股股份32.35万股，每股 回购价格为91.35-93.92元。 ...

格隆汇8月22日丨药明康德(02359.HK)发布公告，2025年8月22日耗资2999.5万元人民币回购32.35万股A 股，回购价格每股91.35-93.92元。 ...

-今日A股共有22只个股换手率超过30%； 【振幅大】 -今日A股共有10只个股振幅超过20%； -N能之光、科创信息、同惠电子等个股振幅居前； 【换手率高】 -主力资金今日净流入计算机、电子、传媒等板块，净流出医药生物、基础化工、有色金属等板块； -东方财富、中兴通讯、昆仑万维、川润股份、同花顺主力资金净流入规模居前，分别净流入19.87亿 元、16.97亿元、12.92亿元、8.89亿元、7.00亿元； -每日互动、歌尔股份、北信源、跨境通、药明康德主力资金净流出规模居前，分别净流出6.23亿元、 5.45亿元、5.09亿元、4.39亿元、4.11亿元。 (本文来自第一财经) -N能之光、南方精工、科创信息等个股换手率居前； 【主力资金】 ...